Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Heart, Lung, and Blood Institute (NHLBI) |
---|---|
Information provided by: | National Institutes of Health Clinical Center (CC) |
ClinicalTrials.gov Identifier: | NCT00483951 |
This study will evaluate volunteers 18 years of age and older to see if they qualify for one of NHLBI's research studies. Tests include the following:
Condition |
---|
Congenital Heart Disease Atherosclerosis Myocardial Ischemia Myocardial Infarction Acquired Heart Disease |
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | Suburban/NHLBI Cardiovascular Disease Screening Protocol |
Study Start Date: | June 2007 |
This is a screening protocol. This protocol allows two functions: 1) the protocol allows physicians in the Suburban/NHLBI Cardiovascular Imaging program to evaluate patients referred to the program with clinically indicated studies and research studies. 2) It is also designed to determine if patients may be suitable candidates for one of our NHLBI research protocols.
Patients greater than or equal to18 years of age referred for possible cardiovascular disease will be enrolled in the protocol for a period of one year. At one year, patients will either be: 1) transferred to one of our specific research MRI or CT protocols, 2) removed from the screening protocol and made inactive, or 3) re-enrolled on the screening protocol with the patient's consent.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
No one will be excluded from this study based on race, gender, or ethnicity.
A. General Inclusion Criteria:
B. General Exclusion Criteria (for all arms):
Test Specific Exclusion Criteria:
A. CT Exclusion Criteria (excludes contrast enhanced CT scan only):
B. Beta Antagonist Exclusions (excluded the use of beta blocker only):
C. MRI Exclusion Criteria (excludes MRI scan only):
D. Exclusions from MRI contrast agents:
E. Vasodilator Exclusions (excludes some vasodilator stress testing):
F. Exclusions from Dobutamine stress MRI only:
G. Exclusion criteria for atropine (given during dobutamine stress echocardiography when target heart rate not achievable with dobutamine alone).
Contact: Patient Recruitment and Public Liaison Office | (800) 411-1222 | prpl@mail.cc.nih.gov |
Contact: TTY | 1-866-411-1010 |
United States, Maryland | |
National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
Bethesda, Maryland, United States, 20892 | |
Suburban Hospital | Recruiting |
Bethesda, Maryland, United States, 20814 |
Study ID Numbers: | 070157, 07-H-0157 |
Study First Received: | June 7, 2007 |
Last Updated: | November 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00483951 |
Health Authority: | United States: Federal Government |
Myocardial Infarction Myocardial Ischemia Atherosclerosis Congenital Heart Disease Valvular Heart Disease |
Heart Disease Cardiovascular Disease Congenital Heart Disease Heart Valve Disease Atherosclerosis |
Atherosclerosis Arterial Occlusive Diseases Heart Diseases Cardiovascular Abnormalities Myocardial Ischemia Vascular Diseases Ischemia |
Arteriosclerosis Heart Valve Diseases Necrosis Congenital Abnormalities Infarction Myocardial Infarction Heart Defects, Congenital |
Pathologic Processes Cardiovascular Diseases |